

PRECEPTORSHIP PROGRAMME

Non-Small-Cell Lung Cancer (NSCLC)

Standards of care, evolving paradigm
and future perspectives

SINGAPORE

13-14 DECEMBER 2016

Co-Chairs Jean-Yves Douillard, CH
Yi-Long Wu, CN

ESMO PRECEPTORSHIP PROGRAMME NON-SMALL-CELL LUNG CANCER

Standards of care, evolving paradigm and future perspectives

Singapore
13-14 December 2016

CO-CHAIRS: Jean-Yves Douillard, Switzerland
Yi-Long Wu, China

SPEAKERS: Jafaar Bennouna, France
Dominique Grunenwald, France
Eiji Iwama, Japan
Keith Kerr, United Kingdom
Kazuhiko Nakagawa, Japan
Egbert F. Smit, Netherlands

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
- To understand the importance of pathology and histoprognostic factors in the management of NSCLC
- To learn about the management of patients after progression, side-effects of treatments, and the use of targeted agents in NSCLC

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Tuesday, 13 December 2016

13:00-14:00	Lunch	
14:00-14:15 15'	Opening and welcome	Chair: Jean-Yves Douillard, CH
15'	Welcome from ESMO, objectives and scientific introduction	Jean-Yves Douillard, CH
14:15-16:15 120'	SESSION 1 Non-metastatic disease	Chair: Yi-Long Wu, CN
30'	Histopathology of NSCLC, IHC markers and pTNM classification	Keith Kerr, UK
20'	State-of-the-art: standard of care for resectable NSCLC - Surgical approach for resectable NSCLC	Dominique Grunenwald, FR
40'	State-of-the-art: standard of care for resectable NSCLC - Adjuvant chemotherapy - Is there a place for neo-adjuvant chemotherapy?	Jafaar Bennouna, FR
30'	Radiotherapy in NSCLC: What are the ESMO Guidelines? - The role of radiation in early stage - RT/CT for unresectable NSCLC - Brain metastasis - Oligometastatic disease	Jean-Yves Douillard, CH
16:15-16:45	Coffee Break	
16:45-17:45 60'	SESSION 2 Audience cases	Chair: Jean-Yves Douillard, CH
3x20'	3 x Participant clinical case discussion	Faculty
19:30	Dinner	

Each 20 minute slot for clinical case discussion includes 10' case presentation plus 10' Q&A / panel discussion.

Wednesday, 14 December 2016

09:00-10:30 90'	SESSION 3 Metastatic NSCLC	Chair: Jean-Yves Douillard, CH
45'	1 st line chemotherapy and contribution of targeted agents	Yi-Long Wu, CN
45'	Maintenance treatment - Chemo maintenance or targeted agents or both?	Egbert F. Smit, NL
10:30-11:00	Coffee Break	
11:00-12:10 70'	SESSION 4 Biomarker driven treatment	Chair: Egbert F. Smit, NL
30'	Biomarker driven treatment of selected NSCLC: EGFR - EGFR TKI in mutant EGFR NSCLC - Mechanisms of resistance and new generation EGFR TKI	Jafaar Bennouna, FR
20'	Tissue or liquid biopsies? For diagnosis, monitoring and early detection of resistance	Eiji Iwama, JP
20'	Biomarker driven treatment of selected NSCLC: ALK EML4 - Crizotinib - Crizotinib resistance - 2 nd generation drugs	Kazuhiko Nakagawa, JP
12:10-13:10	Lunch	
13:10-14:10 60'	SESSION 5 Audience cases	Chair: Jean-Yves Douillard, CH
3x20'	3 x Participant clinical case discussion	Faculty
Each 20 minute slot for clinical case discussion includes 10' case presentation plus 10' Q&A / panel discussion.		
14:10-15:25 75'	SESSION 6 Future development	Chair: Jean-Yves Douillard, CH
30'	Strategic approaches: - Sequence of use of targeted agents and chemotherapy and definition of progression under TKI - Intercalating anti-EGFR with chemotherapy	Yi-Long Wu, CN
30'	Immunotherapy	Jafaar Bennouna, FR
15'	2 nd and later lines of treatment	Egbert F. Smit, NL
15:25-15:40 15'	Conclusion and take home messages	Jean-Yves Douillard, CH